Deaths in cancer trials remain mystery for promising therapy

December 04, 2016

CAR t-cell

The experimental CAR T-cell immunotherapy has shown dramatic results, including long-term cures, for cancer patients with severe disease, but has also left puzzling questions about deaths that have occurred during some tests, Bloomberg reports in a story published by The Washington Post.

“It’s a double-edged sword,” Lewis Silverman, clinical director of Dana-Farber/Boston Children’s Hematologic Malignancy Center, tells Bloomberg. “You have to get through some bad side effects because that’s actually a sign that the CAR-T is doing something.”

  • Read the story. Other outlets that picked up the story include the Chicago Tribune and News OK (The Oklahoman).

Media Inquiries

Ellen Berlin

Kristen Dattoli

Follow Us!

Our Twitter handle is:

Twitter Logo